ES2175152T3 - Fosfolipidos protectores de las radiaciones. - Google Patents

Fosfolipidos protectores de las radiaciones.

Info

Publication number
ES2175152T3
ES2175152T3 ES96940103T ES96940103T ES2175152T3 ES 2175152 T3 ES2175152 T3 ES 2175152T3 ES 96940103 T ES96940103 T ES 96940103T ES 96940103 T ES96940103 T ES 96940103T ES 2175152 T3 ES2175152 T3 ES 2175152T3
Authority
ES
Spain
Prior art keywords
phospholipids
derivatized
disclosed
ether
radiation protective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96940103T
Other languages
English (en)
Inventor
Oren Tirosh
Ron Kohen
Joshua Katzhendler
Yechezkel Barenholz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
Yissum Research Development Co of Hebrew University of Jerusalem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Research Development Co of Hebrew University of Jerusalem filed Critical Yissum Research Development Co of Hebrew University of Jerusalem
Application granted granted Critical
Publication of ES2175152T3 publication Critical patent/ES2175152T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/335—Polymers modified by chemical after-treatment with organic compounds containing phosphorus
    • C08G65/3353—Polymers modified by chemical after-treatment with organic compounds containing phosphorus containing oxygen in addition to phosphorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Birds (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Polymers & Plastics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Luminescent Compositions (AREA)
  • Radiation-Therapy Devices (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)

Abstract

SE EXPONEN NUEVOS FOSFOLIPIDOS VINCULADOS AL ETER, OBTENIDOS COMO DERIVACION CON POLIETILENGLICOL EN EL GRUPO DE LA CABEZA POLAR. LAS DOBLES CAPAS DE LIPIDOS QUE CONTIENEN ESTOS FOSFOLIPIDOS MUESTRAN UNA ELEVADA ESTABILIDAD OSCILATIVA. SE EXPONE IGUALMENTE EL USO DE LIPIDOS VINCULADOS AL ETER Y DERIVADOS DEL PEG EN COMPOSICIONES COSMETICAS HIDRATANTES Y PARA PROTECCION CONTRA LAS RADIACIONES.
ES96940103T 1995-12-11 1996-12-10 Fosfolipidos protectores de las radiaciones. Expired - Lifetime ES2175152T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/570,440 US5817856A (en) 1995-12-11 1995-12-11 Radiation-protective phospholipid and method

Publications (1)

Publication Number Publication Date
ES2175152T3 true ES2175152T3 (es) 2002-11-16

Family

ID=24279658

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96940103T Expired - Lifetime ES2175152T3 (es) 1995-12-11 1996-12-10 Fosfolipidos protectores de las radiaciones.

Country Status (8)

Country Link
US (2) US5817856A (es)
EP (1) EP0900075B1 (es)
AT (1) ATE215360T1 (es)
AU (1) AU705529B2 (es)
DE (1) DE69620473T2 (es)
ES (1) ES2175152T3 (es)
IL (1) IL124732A0 (es)
WO (1) WO1997021429A1 (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817856A (en) * 1995-12-11 1998-10-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Radiation-protective phospholipid and method
US6306433B1 (en) * 1997-08-12 2001-10-23 Pharmacia Ab Method of preparing pharmaceutical compositions
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
US20040247662A1 (en) * 1998-06-25 2004-12-09 Dow Steven W. Systemic immune activation method using nucleic acid-lipid complexes
AU2001226338A1 (en) * 2000-01-11 2001-07-24 Clinical Results, Inc. Dermatological suspensions (micro-matrix)
DE60105977T2 (de) * 2000-02-10 2006-02-23 Liplasome Pharma A/S Auf lipiden basierende systeme zur arzneistoffabgabe
US20050129722A1 (en) * 2002-03-13 2005-06-16 Collagenex Pharmaceuticals, Inc. Water-based delivery systems
KR101076335B1 (ko) * 2002-03-13 2011-10-26 토마스 스쾰트 수성-기재 전달계
ITMI20021033A1 (it) * 2002-05-15 2003-11-17 Acraf Composizione oftalmica acquosa comprendente un lipide mesomorfico liotropico
DK1519714T3 (da) 2002-06-28 2011-01-31 Protiva Biotherapeutics Inc Fremgangsmåde og apparat til fremstilling af liposomer
US7939170B2 (en) * 2002-08-15 2011-05-10 The Rockefeller University Water soluble metal and semiconductor nanoparticle complexes
US8071560B2 (en) * 2004-02-17 2011-12-06 University Of South Florida Materials and methods for reducing inflammation by inhibition of the atrial natriuretic peptide receptor
US20080214437A1 (en) * 2002-09-06 2008-09-04 Mohapatra Shyam S Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases
AU2003268531A1 (en) 2002-09-06 2004-03-29 University Of South Florida Materials and methods for treatment of allergic diseases
US20040166083A1 (en) * 2003-02-26 2004-08-26 The Andrew Jergens Company Personal care water-in-oil emulsion products
EP1610763A2 (en) * 2003-03-31 2006-01-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem Stable liposomes or micelles comprising a sphingolipid and a peg-lipopolymer
AU2004233873B2 (en) 2003-04-25 2010-11-18 The Penn State Research Foundation Method and system for systemic delivery of growth arresting, lipid-derived bioactive compounds
NZ544637A (en) * 2003-07-16 2010-04-30 Protiva Biotherapeutics Inc Lipid encapsulated interfering RNA
EP1664316B1 (en) * 2003-09-15 2012-08-29 Protiva Biotherapeutics Inc. Polyethyleneglycol-modified lipid compounds and uses thereof
EP1727556A2 (en) * 2004-02-17 2006-12-06 University Of South Florida Materials and methods for treatment of inflammatory and cell proliferation disorders
US20050181035A1 (en) * 2004-02-17 2005-08-18 Dow Steven W. Systemic immune activation method using non CpG nucleic acids
ATE536418T1 (de) * 2004-06-07 2011-12-15 Protiva Biotherapeutics Inc Lipidverkapselte interferenz-rna
WO2006020182A2 (en) * 2004-07-16 2006-02-23 Smart Medical Technologies, Llc Centrifuge system
WO2006027786A2 (en) * 2004-09-09 2006-03-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of liposomal glucocorticoids for treating inflammatory states
US20080063702A1 (en) * 2004-09-09 2008-03-13 Yechezkel Barenholz Liposomal Formulations Comprising an Amphipathic Weak Base Like Tempamine for Treatment of Neurodegenerative Conditions
AU2005303389A1 (en) * 2004-11-15 2006-05-18 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combination therapy associating preferably a ceramide with a cytotoxic drug
WO2006066158A2 (en) * 2004-12-14 2006-06-22 Alnylam Pharmaceuticals, Inc. Rnai modulation of mll-af4 and uses thereof
WO2006086992A2 (en) * 2005-02-18 2006-08-24 Liplasome Pharma A/S Drug delivery systems containing phqspholipase a2 degradable lipid prodrug derivatives and the therapeutic uses thereof as. e.g. wound healing agents and peroxisome proliferator activated receptor ligands
CN101365424A (zh) * 2005-12-08 2009-02-11 耶路撒冷希伯来大学伊森姆研究发展公司 通过超声辐射改变脂质体组成的方法
US20070218116A1 (en) * 2006-03-14 2007-09-20 Schwendener Reto A Compositions and methods for the treatment of tumors and tumor metastases
US8298818B2 (en) * 2006-04-28 2012-10-30 University Of Florida Research Foundation, Inc. Self-complementary adeno-associated virus having a truncated CMV-chicken β-actin promoter
CA2600220C (en) * 2006-09-07 2014-12-09 Canadian Blood Services Surface cross-linked lipidic particles, methods of production and uses therefor
PL2279254T3 (pl) 2008-04-15 2017-11-30 Protiva Biotherapeutics Inc. Nowe preparaty lipidowe do dostarczania kwasów nukleinowych
US20120100206A1 (en) 2009-06-11 2012-04-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Targeted liposomes comprising n-containing bisphosphonates and uses thereof
WO2011000106A1 (en) 2009-07-01 2011-01-06 Protiva Biotherapeutics, Inc. Improved cationic lipids and methods for the delivery of therapeutic agents
US9018187B2 (en) 2009-07-01 2015-04-28 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
JP5766188B2 (ja) 2009-07-01 2015-08-19 プロチバ バイオセラピューティクス インコーポレイティッド 固形腫瘍に治療剤を送達するための脂質製剤
EP2531175A2 (en) 2010-02-01 2012-12-12 Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. Liposomes comprising amphipathic drugs and method for their preparation
US9006417B2 (en) 2010-06-30 2015-04-14 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
AU2011342896A1 (en) 2010-12-13 2013-07-04 Quiapeg Pharmaceuticals Ab Functionalized polymers
US10184942B2 (en) 2011-03-17 2019-01-22 University Of South Florida Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer
US10085940B2 (en) 2011-07-13 2018-10-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Liposomes co-encapsulating a bisphosphonate and an amphipathic agent
US10010621B2 (en) 2012-06-12 2018-07-03 Quiapeg Pharmaceuticals Ab Conjugates of biologically active molecules to functionalized polymers
EP3247333B1 (en) 2015-01-20 2021-07-21 Tetraderm Group LLC Versatile topical drug delivery vehicle and multifactorial tissue moisturizer that provides mucosal and skin barrier restoration
US20180071253A1 (en) 2015-03-17 2018-03-15 Lipomedix Pharmaceuticals Ltd. Methods for the treatment of bladder cancer
CN105439827A (zh) * 2016-01-12 2016-03-30 江苏省计量科学研究院 一种1,2-O-双十六烷基-rac-甘油的合成方法
KR20190125310A (ko) 2017-03-10 2019-11-06 퀴아펙 파마슈티칼스 에이비 방출가능한 접합체
JP2021535920A (ja) 2018-09-12 2021-12-23 キアペグ ファーマシューティカルズ アクチエボラグ 放出可能なｇｌｐ−１コンジュゲート
FR3089814B1 (fr) * 2018-12-18 2021-04-02 Oreal Procede de traitement des fibres keratiniques comprenant l’application d’un agent de couplage et d’un phospholipide, composition et utilisation
KR20230124927A (ko) 2020-11-25 2023-08-28 아카제라 메디신즈, 인크. 핵산 전달을 위한 지질 나노입자, 및 관련 사용 방법
CN114796055B (zh) * 2022-05-19 2023-08-15 广东艾粒生物科技有限责任公司 富含脂质体纳米粒的美白敷料及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2408387A2 (fr) * 1975-06-30 1979-06-08 Oreal Compositions a base de dispersions aqueuses de spherules lipidiques
US4426330A (en) * 1981-07-20 1984-01-17 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4534899A (en) * 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
US5153000A (en) * 1988-11-22 1992-10-06 Kao Corporation Phosphate, liposome comprising the phosphate as membrane constituent, and cosmetic and liposome preparation comprising the liposome
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
DE69103487T2 (de) * 1990-07-11 1995-02-16 Quest Int Parfümierte strukturierte Emulsionen in Körperpflegemitteln.
FR2676924B1 (fr) * 1991-05-31 1995-02-03 Saint Laurent Parfums Yves Microemulsion contenant un concentre parfumant et produit correspondant.
JPH07316040A (ja) * 1994-03-29 1995-12-05 Res Dev Corp Of Japan 再構成リポソームと物質導入方法
US5817856A (en) * 1995-12-11 1998-10-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Radiation-protective phospholipid and method

Also Published As

Publication number Publication date
DE69620473D1 (de) 2002-05-08
EP0900075A1 (en) 1999-03-10
IL124732A0 (en) 1999-01-26
DE69620473T2 (de) 2002-11-14
AU7707596A (en) 1997-07-03
US6165501A (en) 2000-12-26
EP0900075B1 (en) 2002-04-03
US5817856A (en) 1998-10-06
AU705529B2 (en) 1999-05-27
ATE215360T1 (de) 2002-04-15
WO1997021429A1 (en) 1997-06-19

Similar Documents

Publication Publication Date Title
ES2175152T3 (es) Fosfolipidos protectores de las radiaciones.
EA199900486A1 (ru) Применение сфингомиелиназы для повышения уровней церамидов в коже и слизистых оболочках, а также содержащие ее дерматологические и косметические композиции, которые удобны для местного применения
ES2054278T3 (es) Utilizacion y composiciones cosmeticas que contienen diorganopolisiloxanos con funcion benzotriazol para la proteccion de la piel y los cabellos.
IT8367659A0 (it) Nuove 3 benzilidencanfore loro procedimento di preparazione e loro utilizzazione per la protezione con tro i raggi ultravioletti
AU653999B2 (en) Compositions having a physiological cooling effect, and active compounds suitable for these compositions
ES2162951T3 (es) Estabilizacion de composiciones de prostaglandina.
ITMI950493A0 (it) Frazioni polifenoliche di te' loro uso e formulazioni che le contengono
IT1203515B (it) Complessi di saponine con fosfolipidi e composizioni farmaceutiche e cosmetiche che li contengono
DE69419909T2 (de) Flammhemmende im wesentlichen halogenfreie epoxydzusammensetzung
ATE173155T1 (de) Mittel zur künstlichen bräunung mit verbesserter stabilität
AR000271A1 (es) Composiciones cosméticas par uso tópico utilizables para el bronceado y/o el tostado artificiales dela piel
EA200000181A1 (ru) Фармацевтические композиции, содержащие витамин d и кальций, их приготовление и терапевтическое применение
DE69811061T2 (de) Kosmetische zusammensetzungen enthaltend ein kationisches polymer mit niedrigem molekulargewicht und einem silikon sowie deren verwendungen
DE69428456T2 (de) Silikon-modifizierte phospholipid-zusammensetzungen
ES2135169T3 (es) Cable resistente a las arborescencias.
ES2057004T3 (es) N-alcoxialquilamidas de hidroxiacidos y composiciones a base de las mismas para el tratamiento de la piel.
WO1997016155A3 (en) Cosmetic and cosmeceutical compositions
DK0487973T3 (da) Topisk lotion indeholdende niclosamid
AU3169089A (en) Use of diorganopolysiloxanes containing a 3-benzylidene- camphor functional group in cosmetics and new cosmetic compositions containing these compounds, intended for protecting the skin and hair
DK0801571T3 (da) Opløselige 2'-chlor-2'-deoxyadenosion-formuleringer
KR980700053A (ko) TiO₂나노피그먼트 및 아실아미노산을 함유하는 자외선-차단 화장품용 조성물(Ultraviolet-Protecting Cosmetic Compositions Containing TiO₂Nanopigments and an Acylaminoacid)
FI925930A0 (fi) En kosmetisk eller dermatologisk blandning innehaollande en diolester
DE69733844D1 (de) SnF2 GEL MIT VERBESSERTER FORMFESTIGKEIT UND STABILITÄT
ES2155244T3 (es) Utilizacion de una silicona filtro para la proteccion de las fibras queratinicas coloreadas artificialmente contra los efectos de las radiaciones uv.
NO932741D0 (no) Kosmetiske eller dermatologiske sammensetninger inneholdende tanniner

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 900075

Country of ref document: ES